Drug Trial Radar · NCT05858736
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Jul 11, 2023
Primary completion
Jul 31, 2026
Study completion Jul 31, 2026
Sponsor
- Lead sponsor
- OncoC4, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- OncoC4 AU Pty Ltd; Avance Clinical Pty Ltd.
- First posted
- May 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody. This is a dose escalation study to identify the maximum toxicity dose (MTD) or the recommended phase 2 dose (RP2D).
Conditions
- Melanoma
- Non Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- High Grade Serous Adenocarcinoma of Ovary
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer
- Endometrial Cancer
- Cervical Cancer
- Renal Cell Carcinoma
- Bladder Cancer
- Esophageal Cancer
- Gastric Cancer
- Gastroesophageal-junction Cancer
- Colorectal Cancer
- Anal Cancer
- Hepatocellular Carcinoma
- Bile Duct Cancer
Interventions
AI-061Drug
A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC- 392 (Anti-CTLA-4) Antibodies.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicity (DLT)Time frame: 21 days after first treatment
- Maximum Toxicity Dose (MTD)Time frame: 21 day after first treatment
- Recommended Phase II Dose (RP2D)Time frame: 21 days after first treatment
- Incidence of treatment emergent adverse events (TEAE)Time frame: From the day with first treatment to 90 days after the last treatment.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
St. Vincent's Private Hospital
Darlinghurst, New South Wales, Australia
Mater Misericordiae Ltd.
Brisbane, Queensland, Australia
Tasman Oncology Research
Southport, Queensland, Australia
Cancer Research SA
Adelaide, South Australia, Australia
Southern Oncology Clinical Research Unit
Bedford Park, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.